These 6 stocks are valued at a combined $4.2 trillion and that could mean trouble for the index.
Read MoreAffimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients […]
Read MoreMarkets yesterday saw one of their most volatile days of the entire year so far, doubling down on trade uncertainty raised when a new tweet from President Donald Trump on Sunday threatened to impose $200 billion in new tariffs this Friday, raising current levels from 10% to the long-feared 25%. On Monday, the market tried […]
Read More